Antagonists of protein-protein interactions made easy?

Journal of Medicinal Chemistry

Volumn 56, Issue 1, 2013, Pages 13-14

  Pellecchia, Maurizio ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE;

FLUORESCENCE POLARIZATION; HETERONUCLEAR MULTIPLE QUANTUM COHERENCE; HYDROPHOBICITY; MOLECULAR RECOGNITION; NOTE; NUCLEAR MAGNETIC RESONANCE; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; SMALL MOLECULE LIBRARIES;

EID: 84872289030     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301837n     Document Type: Note

References (10)

1. Danial, N. N.; Korsmeyer, S. J. Cell death: critical control points Cell 2004, 116 (2) 205-219
2. Placzek, W. J.; Wei, J.; Kitada, S.; Zhai, D.; Reed, J. C.; Pellecchia, M. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy Cell Death Dis. 2010, 1, e40
3. Quinn, B. A.; Dash, R.; Azab, B.; Sarkar, S.; Das, S. K.; Kumar, S.; Oyesanya, R. A.; Dasgupta, S.; Dent, P.; Grant, S.; Rahmani, M.; Curiel, D. T.; Dmitriev, I.; Hedvat, M.; Wei, J.; Wu, B.; Stebbins, J. L.; Reed, J. C.; Pellecchia, M.; Sarkar, D.; Fisher, P. B. Targeting Mcl-1 for the therapy of cancer Expert Opin. Invest. Drugs 2011, 20 (10) 1397-1411
4. Reed, J. C.; Pellecchia, M. Apoptosis-based therapies for hematologic malignancies Blood 2005, 106 (2) 408-418
5. Friberg, A.; Vigil, D.; Zhao, B.; Daniels, R. N.; Burke, J. P.; Garcia-Barrantes, P. M.; Camper, D.; Chauder, B. A.; Lee, T.; Olejniczak, E. T.; Fesik, S. W. Discovery of potent myeloid cell leukemia 1 (Mcl-1) Inhibitors using fragment-based methods and structure-based design J. Med. Chem. 2012, DOI: 10.1021/jm301448p.
6. Muppidi, A.; Doi, K.; Edwardraja, S.; Drake, E. J.; Gulick, A. M.; Wang, H. G.; Lin, Q. Rational design of proteolytically stable, cell-permeable peptide-based selective Mcl-1 inhibitors J. Am. Chem. Soc. 2012, 134 (36) 14734-14737
7. Murray, C. W.; Rees, D. C. The rise of fragment-based drug discovery Nat. Chem. 2009, 1 (3) 187-192
8. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR Science 1996, 274 (5292) 1531-1534
9. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005, 435 (7042) 677-681
10. Lee, E. F.; Czabotar, P. E.; Smith, B. J.; Deshayes, K.; Zobel, K.; Colman, P. M.; Fairlie, W. D. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family Cell Death Differ. 2007, 14 (9) 1711-1713